Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | KNSA |
---|---|---|
09:32 ET | 2910 | 18.71 |
09:39 ET | 100 | 18.68 |
09:41 ET | 189 | 18.76 |
09:48 ET | 1361 | 18.665 |
09:52 ET | 100 | 18.69 |
09:56 ET | 1198 | 18.66 |
09:57 ET | 200 | 18.6503 |
10:03 ET | 100 | 18.62 |
10:06 ET | 2517 | 18.5447 |
10:08 ET | 1545 | 18.48 |
10:10 ET | 300 | 18.46 |
10:12 ET | 1569 | 18.5 |
10:14 ET | 100 | 18.485 |
10:15 ET | 300 | 18.45 |
10:17 ET | 400 | 18.44 |
10:19 ET | 300 | 18.455 |
10:26 ET | 100 | 18.455 |
10:28 ET | 100 | 18.465 |
10:30 ET | 845 | 18.56 |
10:32 ET | 1561 | 18.56 |
10:33 ET | 11647 | 18.615 |
10:35 ET | 200 | 18.64 |
10:37 ET | 1300 | 18.61 |
10:42 ET | 1968 | 18.58 |
10:44 ET | 736 | 18.51 |
10:46 ET | 561 | 18.515 |
10:48 ET | 104 | 18.5 |
10:50 ET | 400 | 18.44 |
10:57 ET | 1447 | 18.395 |
11:00 ET | 200 | 18.33 |
11:02 ET | 1805 | 18.39 |
11:04 ET | 600 | 18.46 |
11:06 ET | 500 | 18.45 |
11:08 ET | 340 | 18.46 |
11:09 ET | 100 | 18.45 |
11:11 ET | 100 | 18.43 |
11:18 ET | 108 | 18.44 |
11:20 ET | 200 | 18.445 |
11:22 ET | 415 | 18.45 |
11:24 ET | 200 | 18.48 |
11:27 ET | 753 | 18.505 |
11:31 ET | 100 | 18.53 |
11:33 ET | 975 | 18.57 |
11:49 ET | 100 | 18.63 |
11:51 ET | 200 | 18.64 |
11:54 ET | 513 | 18.62 |
11:56 ET | 213 | 18.64 |
11:58 ET | 700 | 18.6 |
12:00 ET | 100 | 18.59 |
12:02 ET | 100 | 18.56 |
12:05 ET | 100 | 18.59 |
12:07 ET | 200 | 18.62 |
12:09 ET | 8000 | 18.58 |
12:12 ET | 700 | 18.58 |
12:14 ET | 504 | 18.61 |
12:16 ET | 500 | 18.59 |
12:20 ET | 100 | 18.58 |
12:21 ET | 300 | 18.6 |
12:30 ET | 700 | 18.58 |
12:38 ET | 612 | 18.55 |
12:39 ET | 300 | 18.55 |
12:43 ET | 375 | 18.5797 |
12:50 ET | 500 | 18.53 |
12:59 ET | 565 | 18.5 |
01:06 ET | 119 | 18.5214 |
01:08 ET | 100 | 18.525 |
01:14 ET | 362 | 18.535 |
01:24 ET | 798 | 18.54 |
01:26 ET | 403 | 18.55 |
01:33 ET | 104 | 18.56 |
01:42 ET | 700 | 18.55 |
01:44 ET | 100 | 18.54 |
01:46 ET | 500 | 18.54 |
01:48 ET | 300 | 18.54 |
02:00 ET | 600 | 18.515 |
02:09 ET | 1438 | 18.45 |
02:18 ET | 515 | 18.43 |
02:22 ET | 150 | 18.425 |
02:26 ET | 220 | 18.44 |
02:27 ET | 1163 | 18.46 |
02:31 ET | 600 | 18.43 |
02:33 ET | 100 | 18.42 |
02:36 ET | 887 | 18.41 |
02:40 ET | 100 | 18.44 |
02:44 ET | 500 | 18.41 |
02:49 ET | 600 | 18.39 |
02:51 ET | 200 | 18.4 |
02:54 ET | 1257 | 18.43 |
02:58 ET | 195 | 18.44 |
03:00 ET | 1650 | 18.43 |
03:02 ET | 800 | 18.47 |
03:03 ET | 100 | 18.485 |
03:05 ET | 100 | 18.485 |
03:12 ET | 1212 | 18.48 |
03:14 ET | 734 | 18.52 |
03:16 ET | 450 | 18.5 |
03:18 ET | 2642 | 18.5 |
03:20 ET | 700 | 18.53 |
03:23 ET | 985 | 18.515 |
03:25 ET | 1642 | 18.455 |
03:27 ET | 1132 | 18.47 |
03:30 ET | 1608 | 18.52 |
03:34 ET | 486 | 18.49 |
03:36 ET | 489 | 18.495 |
03:38 ET | 1522 | 18.515 |
03:39 ET | 500 | 18.51 |
03:43 ET | 4500 | 18.5 |
03:45 ET | 6854 | 18.485 |
03:48 ET | 1127 | 18.455 |
03:50 ET | 2423 | 18.44 |
03:52 ET | 1368 | 18.48 |
03:54 ET | 617 | 18.509 |
03:56 ET | 500 | 18.51 |
03:57 ET | 1976 | 18.505 |
03:59 ET | 98357 | 18.57 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Kiniksa Pharmaceuticals Ltd | 1.3B | 218.0x | --- |
Ginkgo Bioworks Holdings Inc | 1.2B | -1.3x | --- |
BioCryst Pharmaceuticals Inc | 1.4B | -6.2x | --- |
Zai Lab Ltd | 1.8B | -5.2x | --- |
Dynavax Technologies Corp | 1.5B | 236.6x | --- |
MannKind Corp | 1.2B | 192.1x | --- |
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. The Company’s ARCALYST is interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. Its KPL-404 is an investigational monoclonal antibody inhibitor of CD40-CD154 interaction. The Company’s Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.3B |
---|---|
Revenue (TTM) | $301.8M |
Shares Outstanding | 70.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.33 |
EPS | $0.09 |
Book Value | $6.23 |
P/E Ratio | 218.0x |
Price/Sales (TTM) | 4.4 |
Price/Cash Flow (TTM) | 121.3x |
Operating Margin | -10.12% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.